Enanta Pharmaceuticals Inc is a biotechnology company that uses a chemistry-based drug discovery approach to develop small-molecule candidates for virology and immunology applications. It focuses on Virology and Immunology. Its active development programs in virology are focused on respiratory syncytial virus, or RSV, and SARS-CoV-2, and Hepatitis B virus. In immunology, the company is engaged in designing and developing potent and selective, oral small molecule inhibitors for the treatment of type 2 inflammatory disease. The company has collaborated with AbbVie, which markets its protease inhibitor paritaprevir, with additional inhibitors in development. The company generates the majority revenue in the form of royalty revenue.
Last trade$9.24
Day change-$1.43 (-13.40%)
Day range$8.82 – $10.99
Volume572,473
Market cap$311M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$310.77M
Price / earnings
—
Price / book
3.07×
Price / sales
4.76×
EV / sales
4.25×
EV / EBITDA
-5.15×
Profitability
Earnings per share
-$2.17
Return on assets
-21.3%
Return on equity
-62.56%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
3.76×
Quick ratio
3.76×
Cash ratio
0.62×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$36.94M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for ENTA, quarterly periods
Line item
Q3 FY2026 Jun 30, 2026
Q2 FY2026 Mar 31, 2026
Q1 FY2026 Dec 31, 2025
Q4 FY2025 Sep 30, 2025
Q3 FY2025 Jun 30, 2025
Q2 FY2025 Mar 31, 2025
Q1 FY2025 Dec 31, 2024
Q4 FY2024 Sep 30, 2024
Revenue
$14.36M
$17.16M
$18.62M
$15.13M
$18.31M
$14.93M
$16.96M
$14.61M
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$14.36M
$17.16M
$18.62M
$15.13M
$18.31M
$14.93M
$16.96M
$14.61M
Selling, general and administrative
$9.47M
$9.57M
$9.01M
$9.7M
$10M
$11.39M
$12.85M
$13.68M
Research and development
$22.13M
$19.44M
$20.86M
$23.81M
$27.21M
$28.07M
$27.66M
$30.78M
Total operating expenses
$31.6M
$29.01M
$29.87M
$33.51M
$37.21M
$39.45M
$40.5M
$44.46M
Operating income
-$17.24M
-$11.85M
-$11.25M
-$18.39M
-$18.89M
-$24.53M
-$23.54M
-$29.85M
Interest expense
-$4.13M
-$3.32M
-$3.08M
-$2.39M
-$1.62M
-$1.71M
-$1.96M
-$2.58M
Income before taxes
-$19.47M
-$13.08M
-$11.91M
-$18.67M
-$18.23M
-$23.95M
-$22.71M
-$29.19M
Income taxes
$36K
$7K
$24K
$32K
$29K
-$1.31M
-$416K
-$363K
Net income
-$19.5M
-$13.09M
-$11.94M
-$18.7M
-$18.26M
-$22.64M
-$22.29M
-$28.82M
Net income attributable to common shareholders
-$19.5M
-$13.09M
-$11.94M
-$18.7M
-$18.26M
-$22.64M
-$22.29M
-$28.82M
EBITDA
-$16.05M
-$10.64M
-$10.02M
-$17.1M
-$17.68M
-$23.32M
-$22.65M
-$29.38M
Basic earnings per share
-$0.67
-$0.45
-$0.42
-$0.87
-$0.85
-$1.06
-$1.05
-$1.36
Diluted earnings per share
-$0.67
-$0.45
-$0.42
-$0.87
-$0.85
-$1.06
-$1.05
-$1.36
Recent news
Company coverage with links to the original publishers.
Enanta Pharmaceuticals reported a Q4 loss of $0.81 per share, slightly beating the consensus estimate of $0.83 loss, but missed revenue expectations with $12.87 million versus the estimated $13.85 million. The company's stock has declined 30.3% year-to-date, significantly underperforming the S&P 500's 10.5% gain. The stock received a Zacks Rank #3 (Hold) rating, suggesting it will perform in line with the market.
BioHarvest Sciences Inc. (BHST) reported a Q3 loss of $0.15 per share, beating EPS estimates but missing revenue expectations with $7.87 million versus the consensus estimate. The company's stock has declined 66.3% year-to-date, significantly underperforming the S&P 500's 11.3% gain. BHST received a Zacks Rank #3 (Hold) rating with mixed estimate revisions.
Immatics (IMTX) reported a quarterly loss of $0.58 per share, missing the consensus estimate of $0.49 by 18.37%, and posted revenues of $7.97 million, missing estimates by 22.12%. The stock has underperformed significantly, down 38.8% year-to-date compared to the S&P 500's 10.3% gain. The company holds a Zacks Rank #3 (Hold) rating with mixed estimate revisions, suggesting near-term performance in line with the market.
Multiple health care stocks experienced significant options trading activity, with various bullish and bearish signals across different companies in the sector.
Enanta Pharmaceuticals released positive Phase 2b trial results for zelicapavir, an oral RSV treatment that demonstrated clinically meaningful symptom reduction in high-risk adult patients, particularly those with chronic conditions.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.